查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1737062

全球甲状腺疾病市场规模（按类型、治疗、给药途径、最终用户、地区、范围和预测）

Global Thyroid Disorder Market Size By Type (Hypothyroidism, Hyperthyroidism), By Treatment (Medications, Radioactive Iodine Therapy), By Route of Administration (Oral, Intravenous), By End User (Hospitals, Clinics), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

甲状腺疾病市场规模及预测

2024 年甲状腺疾病市场规模价值 24.6 亿美元，预计到 2032 年将达到 33.5 亿美元，预测期内（2026-2032 年）的复合年增长率为 3.17%。

甲状腺疾病发病率上升、新型有效联合药物疗法的推出以及需要有效联合药物疗法的病例增加，预计将在预测期内推动市场成长。 《全球甲状腺疾病市场报告》对市场进行了全面评估，包括关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

定义全球甲状腺疾病市场

甲状腺疾病是一种影响甲状腺正常功能的疾病。甲状腺是位于颈部正下方的内分泌腺，负责分泌甲状腺激素，并帮助调节体内各种代谢活动。甲状腺控制新陈代谢的过程，也就是人体细胞利用食物中的能量。新陈代谢会影响体温、心率和消费量。当人体缺乏足够的甲状腺激素时，人体的代谢过程就会减慢。

当甲状腺无法分泌足够的甲状腺激素（甲状腺机能低下症）或分泌过多的甲状腺激素（甲状腺功能亢进症）时，人体的代谢和功能就会受损。体内碘缺乏是导致甲状腺疾病的主要因素。所有甲状腺疾病均可治疗，恢復正常的甲状腺功能。然而，这通常需要药物来维持甲状腺健康。大多数甲状腺疾病患者可以透过手术或放射性碘治疗治癒。

全球甲状腺疾病市场概况

推动市场成长的关键因素包括甲状腺疾病发病率的上升、疾病认知计画的持续推​​进（尤其是在新兴国家），以及用于治疗甲状腺疾病的有效药物联合治疗的开发。全球各国政府机构正在提高人们对甲状腺疾病及时诊断和治疗的认识，从而推动市场的成长。此外，製药商也积极支持认知宣传活动，并实施推广策略以提高公众认知度，这有望推动市场的成长。

甲状腺疾病市场的主要驱动力是碘缺乏患者数量的不断增长。甲状腺相关疾病研发和製药领域的投资增加可能会推动市场发展。然而，诸如放射性碘 (RAI) 疗法等治疗方法费用高昂以及现有治疗药物的副作用等因素可能会在一定程度上抑制市场成长。

目录

第 1 章全球甲状腺疾病市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

4. 全球甲状腺疾病市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型

5. 全球甲状腺疾病市场（按类型）

  • 概述
  • 甲状腺机能低下症
  • 甲状腺功能亢进

6. 全球甲状腺疾病市场（依治疗）

  • 概述
  • 药物治疗
  • 放射性碘治疗
  • 外科治疗

7. 全球甲状腺疾病市场（依给药途径）

  • 概述
  • 口服
  • 静脉注射
  • 其他的

8. 全球甲状腺疾病市场（依最终用户）

  • 概述
  • 医院
  • 诊所
  • 其他的

9. 全球甲状腺疾病市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

第十章全球甲状腺疾病市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十一章 公司简介

  • AbbVie Inc.
  • Pfizer Inc.
  • Merck & Co.
  • Lannett Company, Inc.
  • Allergan PLC
  • Mylan NV
  • GlaxoSmithKline PLC
  • Novartis AG
  • RLC LABS
  • Abbott Laboratories

第十二章 附录

  • 相关调查
简介目录
Product Code: 49234

Thyroid Disorder Market Size And Forecast

Thyroid Disorder Market size was valued at USD 2.46 Billion in 2024 and is projected to reach USD 3.35 Billion by 2032, growing at a CAGR of 3.17 % during the forecast period 2026-2032.

The rising number of thyroid gland disorders, the introduction of new effective combination drug therapies, and the growing number of cases requiring effective combination drug therapies are some of the factors anticipated to foster market growth during the forecast period. The Global Thyroid Disorder Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors playing a substantial role in the market.

Global Thyroid Disorder Market Definition

Thyroid disorders are medical conditions affecting the proper functioning of the thyroid gland. The thyroid gland is an endocrine gland located in the middle of lower the neck and is responsible for the production of thyroid hormones which help to regulate various metabolic activities in the body. The thyroid controls the body's cells use energy from food, a process called metabolism. Among other things, metabolism affects the body's temperature, heartbeat, and how well the body burns calories. If the body doesn't have enough thyroid hormone, human body processes slow down.

When the thyroid gland does not produce enough thyroid hormones (hypothyroidism) or too much hormone (hyperthyroidism), the metabolism and functioning of the body are disrupted. The lack of iodine in the body is a major factor that leads to thyroid disorders. All thyroid diseases can be treated, resulting in normal thyroid function. However, this frequently requires being on medication to maintain a normal thyroid state. Most patients with thyroid disorders can be cured through surgery and radioactive iodine treatments.

Global Thyroid Disorder Market Overview

The major factors that drive the growth of the market include an increase in the incidence of thyroid gland disorder, a rise in the number of disease awareness programs, especially in developing countries, and the development of effective combination drug therapies to treat thyroid gland disorder. A government organization across the globe has increased the awareness about timely diagnosis and treatment of thyroid disorders hence promoting the growth of the market. In addition, pharmaceutical manufacturers are also undertaking initiatives to support awareness campaigns or implement promotional strategies to create awareness anticipated to propel the growth of the market.

The market for thyroid disorders is primarily driven by the increasing number of patients with iodine deficiency cause of very less good sources of iodine in the diet can drive the market growth. Research and the development of medicines for thyroid-related disorders and an increase in the investments made in the pharmaceutical sector can drive the market. However, factors such as the high cost of treatment procedures such as radioactive iodine (RAI) therapy and side effects related to the available therapeutics might restrain the market growth to an extent.

Global Thyroid Disorder Market: Segmentation Analysis

The Global Thyroid Disorder Market is Segmented on the basis of Type, Treatment, Route Of Administration, End User, and Geography.

Thyroid Disorder Market, By Type

  • Hypothyroidism
  • Hyperthyroidism

Based on Type, The market is bifurcated into Hypothyroidism and Hyperthyroidism. If the body makes too much thyroid hormone, the body can develop a condition called hyperthyroidism. If the body makes too little thyroid hormone, it's called hypothyroidism. Both conditions are serious and need to be treated with effective drug therapies. Hypothyroidism is expected to gain significant traction over the forecast period. A growing population base diagnosed with the condition and the rising prevalence of iodine deficiency population across the globe is some of the factors that boost the market growth.

Thyroid Disorder Market, By Treatment

  • Medications
  • Radioactive Iodine Therapy
  • Surgery

Based on Treatment, The market is bifurcated into Medications, Radioactive Iodine Therapy and Surgery. Medication that boosts your levels of thyroid hormone is an easy way to treat hypothyroidism. It's not a cure, but it can keep patients' conditions under control for the long term. Also, radioactive iodine therapy is the most widely recommended permanent treatment of hyperthyroidism. This treatment takes advantage of the fact that thyroid cells are the only cells in the body that can absorb iodine.

Thyroid Disorder Market, By Route of Administration

  • Oral
  • Intravenous
  • Others

Based on the Route Of Administration, The market is bifurcated into Oral, Intravenous, and Others. The oral route of the administration segment is the largest contributor toward market growth. Most of the medications available in the market are in the form of tablets or pills and can be easily administered by patients.

Thyroid Disorder Market, By End User

  • Hospitals
  • Clinics
  • Others

Based on End Users, The market is bifurcated into Hospitals, Clinics, and Others.

Thyroid Disorder Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Regional Analysis, The Global Thyroid Disorder Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America is dominating the thyroid gland disorder market. Multinational companies are frequently involved in raising awareness in American society through campaigns driving the growth of the market in the region. The Asia Pacific is expected to have significant growth during the forecast period owing to the growing population base affected with thyroid disorder is increasing demand for drugs that are further expected to boost the growth of the market.

Key Players

The "Global Thyroid Disorder Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are AbbVie Inc., Pfizer Inc., Merck & Co., Inc., Lannett Company, Inc., Allergan plc., Mylan N.V., GlaxoSmithKline plc., Novartis AG, RLC LABS, Inc., and Abbott Laboratories.

  • The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL THYROID DISORDER MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL THYROID DISORDER MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model

5 GLOBAL THYROID DISORDER MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Hypothyroidism
  • 5.3 Hyperthyroidism

6 GLOBAL THYROID DISORDER MARKET, BY TREATMENT

  • 6.1 Overview
  • 6.2 Medications
  • 6.3 Radioactive Iodine Therapy
  • 6.4 Surgery

7 GLOBAL THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION

  • 7.1 Overview
  • 7.2 Oral
  • 7.3 Intravenous
  • 7.4 Others

8 GLOBAL THYROID DISORDER MARKET, BY END USER

  • 8.1 Overview
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Others

9 GLOBAL THYROID DISORDER MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Rest of the World
    • 9.5.1 Latin America
    • 9.5.2 Middle East and Africa

10 GLOBAL THYROID DISORDER MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Development Strategies

11 COMPANY PROFILES

  • 11.1 AbbVie Inc.
    • 11.1.1 Overview
    • 11.1.2 Financial Performance
    • 11.1.3 Product Outlook
    • 11.1.4 Key Developments
  • 11.2 Pfizer Inc.
    • 11.2.1 Overview
    • 11.2.2 Financial Performance
    • 11.2.3 Product Outlook
    • 11.2.4 Key Developments
  • 11.3 Merck & Co.
    • 11.3.1 Overview
    • 11.3.2 Financial Performance
    • 11.3.3 Product Outlook
    • 11.3.4 Key Developments
  • 11.4 Lannett Company, Inc.
    • 11.4.1 Overview
    • 11.4.2 Financial Performance
    • 11.4.3 Product Outlook
    • 11.4.4 Key Developments
  • 11.5 Allergan PLC
    • 11.5.1 Overview
    • 11.5.2 Financial Performance
    • 11.5.3 Product Outlook
    • 11.5.4 Key Developments
  • 11.6 Mylan N.V.
    • 11.6.1 Overview
    • 11.6.2 Financial Performance
    • 11.6.3 Product Outlook
    • 11.6.4 Key Developments
  • 11.7 GlaxoSmithKline PLC
    • 11.7.1 Overview
    • 11.7.2 Financial Performance
    • 11.7.3 Product Outlook
    • 11.7.4 Key Developments
  • 11.8 Novartis AG
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 RLC LABS
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Abbott Laboratories
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

12 APPENDIX

  • 12.1 Related Research